

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete If Known

Application Number	10/576,981
Filing Date	March 2, 2007
First Named Inventor	Martin Leonard Ashdown
Art Unit	1648
Examiner Name	Zachariah Lucas
Attorney Docket Number	5517-18

Sheet 1 of 11

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	5057423	10/15/91	Hiserodt et al.	
	2	5308626	05/03/94	Landucci et al.	
	3	6090392	07/18/00	Berman	
	4	5141867	08/25/92	Ivanoff et al.	
	5	5814639	09/29/98	Liotta et al.	
	6	2002/0954542	07/18/02	Leskovar	
	7	2003/0228320	12/11/03	Ashdown	
	8	2005/0180971	08/18/05	Ashdown	
	9	2008/0248022	10/09/08	Ashdown	
	10	2009/0041760	02/12/09	Ashdown	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ ; Number ⁴ ; Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	11	DE 4120296	03/19/92	Tilgner Regina		(translated abstract)
	12	EP 0374207	06/27/90	Leskovar Peter		(Believed to correspond to WO 89/09620 provided herein)
	13	EP 0358154	03/14/90	Nippon Kayaku KK		
	14	EP 0656778	06/14/95	Univ. Georgia		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT****Complete if Known**

Application Number	10/576,981
Filing Date	March 2, 2007
First Named Inventor	Martin Leonard Ashdown
Art Unit	1648
Examiner Name	Zachariah Lucas
Attorney Docket Number	5517-18

Sheet	2	of	11
-------	---	----	----

	15	EP 0736533	10/09/96	Sqibb Bristol Myers Co		
	16	WO 02/45735	06/13/02	Univ Technologies Int. et al.		
	17	WO 06/026821	03/16/06	Immunaid Pty Ltd. et al.		
	18	WO 1993/19183	09/30/93	Univ Massachusettes Medical		
	19	WO 1995/20660	08/03/95	Univ Massachusettes Medical		
	20	WO 2005/034995	04/21/05	Chiron Corp		
	21	WO 2005/040816	05/06/05	Immunaid Pty Ltd		
	22	WO 2005/070090	08/04/05	Univ California		
	23	WO 2005/072777	08/11/05	Curix Aps		
	24	WO 89/09620	10/19/89	Leskovar Peter		(translated abstract)
	25	WO 90/07119	06/28/90	Immunodiagnostics Inc		
	26	WO 91/09872	07/11/91	Univax Biolog Inc		
	27	WO 92/22654	12/23/92	Microgenesys Inc		
	28	WO 96/30025	10/03/96	The Wellcome Foundation Limited		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number	10/576,981
Filing Date	March 2, 2007
First Named Inventor	Martin Leonard Ashdown
Art Unit	1648
Examiner Name	Zachariah Lucas
Attorney Docket Number	5517-18

Sheet	3	of	11
-------	---	----	----

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner Initials*	Cite No. ¹	
	29	ABC Online, "AM- Cells Switched off for tumour treatment", March 12, 2009, http://www.abc.net.au/am/content/2008/s2513799.htm , accessed April 5, 2009
	30	Annunziato, et al., "Phenotype, Localization, and Mechanism of Suppression of CD4+ CD25+ Human Thymocytes," The Journal of Experimental Medicine, vol. 196, no. 3, pp. 379-387, August 5, 2002
	31	Babbe, et al., "Clonal Expansions of CD8+ T Cells Dominate the T Cell Infiltrate in Active Multiple Sclerosis Lesions as Shown by Micromanipulation and Single Cell Polymerase Chain Reaction," The Journal of Experimental Medicine, vol. 192, no. 3, pp. 393-404, August 7, 2000
	32	BARIN. F. et al.; Virus Envelope Protein of HTLV-III Represents Major Target Antigen for Antibodies in AIDS Patients; May 31, 1985; pp. 1094-1096; V. 228; Science; Gale Group Information Integrity
	33	BATAILLE. R.. et al, -Cytokines and lymphoplasmocytic proliferations: essential role or interleukin 6. xp. 002351766. February 1. 1993. La Revue du praticien. Vol. 43. No.3. pgs 275-278.
	34	Belharz et al., "Timed ablation of regulatory CD4+ T cells can prevent murine AIDS progression" J Immunol 2004, 172:4917-4925
	35	BEILHARZ et al., "Prevention of Murine AIDS by timed immune regulator cell ablation", Journal of Interferon and Cytokine Research, vol. 22, no. suppl. 1, October 2002, pages S-177
	36	Belkaid et al., "Natural regulatory T cells in infectious disease" Nature Immunol 2005, 6(4):353-360
	37	BERD. D "Effect of Low Dose Cyclophosphamide on the Immune System of Cancer Patients: Reduction of T- Suppressor Function without Depletion of the C08+ Subset." XP-002351767 Cancer Research. Vol. 47. Issue 12, June 15, 1987.
	38	Beyer et al., "Regulatory T cells in cancer" Blood 2006, 108(3):804-811
	39	Brandt et al., "Effect of antiviral treatments on the bone marrow in murine AIDS" Blood Cells, Molecules and Diseases 1995, 21 (12):109-118
	40	Bretz, et al., "Inflammatory Cytokine Regulation of Fas-mediated Apoptosis in Thyroid Follicular Cells," The Journal of Biological Chemistry, vol. 274, no. 36, pp. 25433-25438, September 3, 1999
	41	Bruzzzone, et al., "Temporal Patterns of C-Reactive Proteins and Other Acute Phase Proteins After Kidney Transplantation," Transplantation Proceedings, vol. XIX, no. 5, pp. 3727-3730, October 1987

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete If Known

Application Number	10/576,981
Filing Date	March 2, 2007
First Named Inventor	Martin Leonard Ashdown
Art Unit	1648
Examiner Name	Zachariah Lucas
Attorney Docket Number	5517-18

Sheet	4	of	11
-------	---	----	----

42	Carcelain G. et al. "Reconstitution of CD4+ T lymphocytes in HIV-infected individuals following antiretroviral therapy". Curr Opin Immunol. 2001 Aug; 13(4):483-8.
43	CARINI et al. (1994) AIDS Res. Hum. Retroviruses 10:121-130
44	CHATTOPADHYAY, SISIR K. et al.; Structure of Endogenous Murine Leukemia Virus DNA in Mouse Genomes; October. 1980. pp. 5774-5778; V. 77. No. 10; Proc. Natl. Acad. Sci. USA; Biochemistry
45	Cho, et al., "Identification of Serum Amyloid A Protein As a Potentially Useful Biomarker to Monitor Relapse of Nasopharyngeal Cancer by Serum Proteomic Profiling," Clinical Cancer Research, vol. 10, pp. 43-52, January 1, 2004
46	COLL, J. et al.; Antibodies to Human Immunodeficiency Virus (HIV-1) in Autoimmune Diseases: Primary Sjogren's Syndrome. Systemic Lupus Erythematosus, Rheumatoid Arthritis and Autoimmune Thyroid Diseases; December 21.1995; DD. 451-457; V. 14. No.4; Clinical Rheumatology
47	Cunningham RK et al. "Murine AIDS: a model for the human disease or a distinct entity?" Immunol Res. Vol.13(1994), pp 21-28.
48	DENNEHY. PENELOPE H; Active Immunization in the United States: Developments over the Past Decade. Clinical Microbiology Reviews; October. 2001; pp. 872-908; V. 14. No.4; American Society for Microbiology
49	Dias et al., "Animal models used for the evaluation of antiretroviral therapies" in Current HIV Research 2006, 4(4):431-446, Abstract only. On the world wide web at http://www.bentham.org/chivr/contabs/chiv4-4.htm
50	Dittmer et al., "Functional impairment of CD8+ T cells by regulatory T cells during persistent retroviral infection" Immunity 2004, 20:293-303
51	Elliott, et al., "Suppression of Fever and the Acute-Phase Response in a Patient with Juvenile Chronic Arthritis Treated with Monoclonal Antibody to Tumour Necrosis Factor- α (cA2)," British Journal of Rheumatology, vol. 36, no. 5, pp. 589-593, 1997
52	Errante D. et al. "Hodgkin's disease in 35 patients with HIV infection: an experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF". Ann Oncol. 1999 Feb; 10(2): 189-95.
53	Fraternali et al., "Repeated cycles of alternate administration of fludarabine and zidovudine plus didanosine inhibits murine AIDS and reduces proviral DNA content in lymph nodes to undetectable levels" Virology 2002, 302:354-362
54	Freed, et al., "Early Detection of Renal Allograft Rejection by Serial Monitoring of Serum C-Reactive Protein," Transplantation, vol. 37, no. 2, pp. 215-218, February 1984
55	Fu, et al., "CD4+ CD62+ T-Regulatory Cell Subset Has Optimal Suppressive and Proliferative Potential," American Journal of Transplantation, vol. 4, no. 1, pp. 65-78, January 2004

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT****Complete if Known**

Application Number	10/576,981
Filing Date	March 2, 2007
First Named Inventor	Martin Leonard Ashdown
Art Unit	1648
Examiner Name	Zachariah Lucas
Attorney Docket Number	5517-18

Sheet	5	of	11
-------	---	----	----

56	FUJITA et al., "The Value of Acute-Phase Protein Measurements After Curative Gastric Cancer Surgery", Arch. Surg. 1999, 134: 73-75
57	Gaur et al., "Role of a cytotoxic- T-lymphocyte epitope-defined, alternative gag open reading frame in the pathogenesis of a murine retrovirus-induced immunodeficiency syndrome" J Virol 2005, 79(7):4308-4315
58	GAVIN, MARC A. et al., Homeostasis and Anergy of CD4+CD25+ Suppressor T Cells In Vivo; December 10, 2001; pp. 33-41; V. 3, No.1; Howard Hughes Medical Institute, University of Washington; Nature Publishing Group http://immunol.nature.com
59	Gelinas, et al., "Immunotherapy for Alzheimer's disease," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 2, pp. 14657-14662, October 5, 2004
60	GEORGE et al., "Immunokinetics of Autoreactive CD4 T Cells in Blood: A Reporter for the "Hit-and-Run" Autoimmune Attack on Pancreas and Diabetes Progression", Journal of Autoimmunity vol. 23 (2004) pp. 151-160
61	GHYKA G et al. "An Experimental Model Comparing the Antineoplastic and the Immunosuppressive Effects of some Cytostatics- XP-02351730 Archives roumaines de pathologie experimentales et de microbiologie. Romania 1989 Jan-March
62	GORDON. A. et al., 'Cisplatin Vinblastine and Bleomycin Combination Therapy In Resistant Gestational IB.F./ 4 Trophoblastic Disease," XP-002351699 Cancer. vol. 56. No.7. 1986 pgs 1407-1410
63	Goverman, "Tolerance and autoimmunity in TCR transgenic mice specific for myelin basic protein: Immunological Reviews, vol. 169, no. 1, pp. 147-159, June 1999
64	HAMAJIMA et al. (1997) Clin. Immunol. Immunopathol. 83:179-184
65	HARTLEY, JANET W. et al.; Retrovirus-Induced Murine Acquired Immunodeficiency Syndrome: Natural History of Infection and Differing Susceptibility of Inbred Mouse Strains; March, 1989; pp. 1223-1231; Vol. 63, No.3; Journal of Virology; American Society for Microbiology
66	Herniou et al., "Retroviral diversity and distribution in vertebrates" J Virol 1998, 72(7):5955-5966
67	Hill, et al., "Total Body Irradiation and Acute Graft-Versus-Host Disease: The Role of Gastrointestinal Damage and Inflammatory Cytokines," Blood, vol. 90, no. 8, pp. 3204-3213, October 15, 1997
68	HIROAKI MITSUYA et al.; Targeted Therapy of Human Immunodeficiency Virus-Related Disease; July. 1991; 52 pp. 2369-2381; V. 5; The FASEB Journal
69	HIURA, et al., "Both Regulatory T Cells and Antitumor Effector T Cells are primed in the same draining lymph nodes during tumor progression", Journal of Immunology, 2005, pp. 5058-5066

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT****Complete if Known**

Application Number	10/576,981
Filing Date	March 2, 2007
First Named Inventor	Martin Leonard Ashdown
Art Unit	1648
Examiner Name	Zachariah Lucas
Attorney Docket Number	5517-18

Sheet 6 of 11

70	HOLCOMBE et al., "The Immunosuppressive Agent 15-Deoxyspergualin Functions by Inhibiting Cell Cycle Progression and Cytokine Production Following Naïve T Cell Activation", Journal of Immunology, vol. 169, no. 9, pp. 4982-4989, 2002
71	HRYNIEWICZ et al., "CTLA-4 blockage decreases TGF-B, IDO, and viral RNA expression in tissues of SIV mac251-infected macaques", Blood, vol. 108, no. 12, December 1, 2006
72	IMAMI et al. (1999) Clin. Exp. Immunol. 118: 78-86
73	IMAMI et al., "Development of immunotherapeutic strategies for HIV-1", Expert Opinion, vol. 1, no. 5, September 2001, pp. 803-816
74	Iwashiro et al., "Immunosuppression by CD4+ regulatory T cells induced by chronic retroviral infection" PNAS 2001, 98(16): 9226-9230
75	Jonuleit, et al., "Identification and Functional Characterization of Human CD4+ CD25+ T Cells with Regulatory Properties Isolated from Peripheral Blood," The Journal of Experimental Medicine, vol. 193, no. 11, pp. 1285-1294, June 4, 2001
76	KANAI et al. (1996) J. Immunol. 157:3681-3687
77	Keimowitz, "Dementia Improvement With Cytotoxic Chemotherapy: A Case of Alzheimer Disease and Multiple Myeloma," Archives of Neurology, vol. 54, no. 4, pp. 485-488, April 1997
78	KILBY, J. MICHAEL MD et al.; Recurrence of the Acute HIV Syndrome After Interruption of Antiretroviral Therapy in a Patient with Chronic HIV Infection: A Case Report; September 19, 2000; pp. 435-438; V. 133(6); Annals of Internal Medicine; American College of Physicians
79	KINTER et al., "CD25+ CD4+ Regulatory T Cells from the Peripheral Blood of Asymptomatic HIV-infected individuals Regulate CD4+ and CD8+ HIV-specific T Cell Immune Responses in vitro and are associate with favorable clinical markers of disease status", Journal of Experimental Medicine, vol. 200, no. 3, pp. 331-343, August 2, 2004
80	KINTER et al., "Suppression of HIV-specific T cell activity by lymph node CD25+ regulatory T cells from HIV-infected individuals", PNAS, vol. 104, no. 9, pp. 3390-3395, February 27, 2007
81	KNOECHEL et al., "Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen", JEM, vol. 202, November 21, 2005, 12 pages
82	Kohm, et al., "CD4+ CD25+ Regulatory T Cells Suppress Antigen-Specific Autoreactive Immune Responses and Central Nervous System Inflammation During Active Experimental Autoimmune Encephalomyelitis," The Journal of Immunology, vol 169, no. 9, pp. 4712-4716, November 1, 2002
83	Kukreja, et al., "Autoimmunity and Diabetes," The Journal of Clinical Endocrinology & Metabolism, vol. 84, no. 12, pp. 4371-4378, December 1999

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT****Complete if Known**

Application Number	10/576,981
Filing Date	March 2, 2007
First Named Inventor	Martin Leonard Ashdown
Art Unit	1648
Examiner Name	Zachariah Lucas
Attorney Docket Number	5517-18

Sheet 7 of 11

84	Liang et al., "Murine AIDS, a key to understanding retrovirus-induced immunodeficiency" Virallimmunol1996, 9 (4):225-239; Abstract only. PMID: 8978019; PubMed, Indexed for MEDLINE
85	LIFSON, JEFFREY D. et al.; Containment of Simian Immunodeficiency Virus Infection: Cellular Immune Responses and Protection from Rechallenge following Transient Postinoculation Antiretroviral Treatment; March. 2000; DP. 2584-2593; V. 74. No.6; Journal of virology: American Society of Microbiology
86	LIM et al., "Cell surface markers of regulatory T cells are not associated with increased forkhead box p3 expression in blood CD4+ T cells from HIV-infected patients responding to antiretroviral therapy", Immunology and Cell Biology, 2006, 84, 530-536
87	LIM et al., "Proportions of circulating T cells with a regulatory cells phenotype increase with HIV-associated immune activation and remain high on antiretroviral therapy," AIDS 2007, vol. 21, pp. 1525-1534
88	LORI et al., "Hydroxyurea and HIV: 5 years later -- from antiviral to immune-modulating effects", AIDS (London, England) 20 Aug. 1999, vol. 13, no. 12, pp. 1433-1442
89	LORI et al., "Targeting HIV Reservoirs and reconstituting the immune system", AIDS research and human Retroviruses, vvol. 15, no. 18, 1999, pp. 1597-1617
90	MAHMOUD et al., "The Role of C-Reactive Protein as a Prognostic Indicator in Advanced Cancer," Current Oncology Reports 2002 4:250-255.
91	MASON et al., "Expression of Norwalk Virus Capsid Protein in Transgenic Tobacco and Potato and its Oral Immunogenicity in Mice," Proc. Natl. Acad. Sci. USA, Vol. 93, pp 5335-5340, May 1996.
92	Maury, et al., "Comparative study of serum amyloid-related protein SAA, C-reactive protein, and B2-microglobulin as markers of renal allograft rejection," Clinical Nephrology, vol. 22, no. 6, pp. 284-292, date unknown
93	MCGUIRK, PETER et al.; Pathogen-Specific Regulatory T Cells Provoke a Shift in the Th1/Th2 Paradigm in Immunity to Infectious Diseases; September, 2002; pp. 450-455; V. 23 No.9; TRENDS in Immunology; Elsevier Science Ltd
94	MCMILLAN et al. Disease of the Colon & Rectum 1997; 40: 1068-1071
95	MCMILLAN et al. The American Journal of Surgery 1995, 170:319-322
96	Medline Abstract Accession No. PMID 10228499; AVERSA, S.M., et al.; Tumori; Jan.-Feb. 1999, 85(1),54-59.
97	Medline Abstract Accession No. PMID 10950369; DEZUBE, B.J.; Semin Oneal; August 2000, 27(4),424-430.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/576,981
				Filing Date	March 2, 2007
				First Named Inventor	Martin Leonard Ashdown
				Art Unit	1648
				Examiner Name	Zachariah Lucas
Sheet	8	of	11	Attorney Docket Number	5517-18

98	Medline Abstract Accession No. PMID 8959247; ZANUSSI, S., et al.; AIDS Res Hum Retroviruses; December 10, 1996; 12(18), 1703-1707.
99	MEDSTRAND et al., "Characterization of Novel Reverse transcriptase encoding human endogenous retroviral sequences similar to type A and type B retroviruses: Differential transcription in normal human tissues", Journal of Virology, Nov. 1993, vol. 67, no. 11, pp. 6778-6787
100	MEHIGAN et al. Changes in T cell subsets, interleukin-6, and C-reactive protein after laparoscopic and open colorectal resection for malignancy", Surg. Endosc. 2001; 15:1289-1293
101	Miller et al., "Human immunodeficiency virus and AIDS: insights from animal lentiviruses" J Virol 2000, 74 D (16):7187-7195
102	MIYAZONO et al. "Surgical Maneuvers Enhance Molecular Detection of Circulating Tumor Cells During Gastric Cancer Surgery", Annals of Surgery 2001, 233: 189-194
103	Monsonogo, et al., "Immunotherapeutic Approaches to Alzheimer's Disease," Science, vol. 302, pp. 834-838, October 31, 2003
104	MOORE, JOHN P. et al.; MINIREVIEW Genetic Subtypes. Humoral Immunity. and Human Immunodeficiency Virus Type 1 Vaccine Development; July, 2001; pp. 5721-5729; V. 75, No. 13; Journal of Virology; American Society for Microbiology
105	Morgan, et al., "CD25+ Cell Depletion Hastens the Onset of Severe Disease in Collagen-Induced Arthritis," Arthritis & Rheumatism, vol. 48, no. 5, pp. 1452-1460, May 2000
106	MORSE et al., "Retrovirus-induced immunodeficiency in the mouse: MAIDS as a model for AIDS", AIDS, 1992, vol. 6, pp. 607-621
107	MORTENSEN, "C-Reactive Protein, Inflammation, and Innate Immunity", Immunologic Research, 2001, vol. 24, no. 2, pp. 163-176
108	Murphy, et al., "New strategies for preventing graft-versus-host disease," Current Opinion in Immunology, vol. 11, no. 5, pp. 509-515, October 1, 1999
109	Nasti et al. "A risk and benefit assessment of treatment for AIDS-related Kaposi's sarcoma" Drug Safety, 1999 May; 20(5):403-425
110	Orenstein R "Looking beyond highly active antiretroviral therapy: drug-related hepatotoxicity in patients with human immunodeficiency virus infection" Pharmacotherapy Vol. 22(2002) pp1468-78.
111	ORTIZ, GABRIEL M. et al.; HIV-1-Specific Immune Responses in Subjects Who Temporarily Contain Virus Replication After Discontinuation of Highly Active Antiretroviral Therapy, August 16, 1999; V. 0, No. 1999; J. Clin Invest.; American Society for Clinical Investigation
112	Pepys, et al., "C-reactive protein: a critical update," The Journal of Clinical Investigation, vol. 111, no. 12, pp. 1805-1812, June 2003

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT****Complete if Known**

Application Number	10/576,981
Filing Date	March 2, 2007
First Named Inventor	Martin Leonard Ashdown
Art Unit	1648
Examiner Name	Zachariah Lucas
Attorney Docket Number	5517-18

Sheet 9 of 11

113	RACKE et al., "Intravenous Antigen Administration as a Therapy for Autimmune Demyelinating Disease", Annals of Neurology, vol. 39, no. 1, pp. 46-56, 1996
114	RAKOWICZ-SZULCZYNSKA, EVA M. et al.; Human Immunodeficiency Virus Type 1-Like DNA Sequences and Immunoreactive Viral Particles with Unique Association with Breast Cancer; September, 1998; pp. 645-653; V. 5, No.5; Clinical and Diagnostic Laboratory Immunology; American Society for Microbiology
115	RAKOWICZ-SZULCZYNSKA, EVA M.; Relevance of the Viral RAK Alpha Gene in Diagnosis of Malignant Versus Nonmalignant Tumors of the Ovary and Uterus; May, 2000; pp. 360-365; V. 7, No.3; Clinical and Diagnostic Laboratory Immunology; American Society for Microbiology
116	Read et al., "CD4+ regulatory T cells" Curr Opin Immunol 2001, 13:644-649
117	Rossi et al., "Inhibition of murine AIDS by a heterodinucleotide of azidothymidine and 9-(R)-2-(phosphonomethoxypropyl)adenine" J Antimicrobial Chemo 2002,50:639
118	Rouse et al., "Regulatory T Cells in virus infections" Immunol Rev 2006, 212:272-286
119	SAHNI et al., "HIV Vaccine Strategies - an Update," Armed Forces Medical College, Vol. 60, No. 2, 2004, pages 157-164
120	Sakaguchi et al., "Regulatory T cells: key controllers of immunologic self-tolerance" Cell 2000, 101:455-458
121	Santamaria, "Effector lymphocytes in autoimmunity," Current Opinion in Immunology, vol. 13, no. 6, pp. 663-669, December 1, 2001
122	Shepherd FA et al. "Combination chemotherapy and a-interferon in the treatment of Kaposi's sarcoma associated with acquired immune deficiency syndrome" CMAJ 139 (1988):635-639.
123	SHIH et al., "Detection of Multiple, Novel Reverse Transcriptase Coding Sequences in Human Nucleic Acids: Relation to Primate Retroviruses," Journal of Virology, Jan 1989, vol. 63, no. 1, pp 64-75
124	Smith, et al., "Use of Two-Dimensional Gel Electrophoresis to Measure Changes in Synovial Fluid Proteins from Patients with Rheumatoid Arthritis Treated with Antibody to CD4," Clinical and Diagnostic Laboratory Immunology, vol. 8, no. 1, pp. 105-111, January 2001
125	Speiser, et al., "TNF Receptor p55 Controls Early Acute Graft-Versus-Host Disease," The Journal of Immunology, vol. 158, no. 11, pp. 5185-5190, June 1, 1997
126	STOTT, J. et al.; Candidate Vaccines Protect Macaques Against Primate Immunodeficiency Viruses; 1998; pp. S-265-S-270; V. 14. Suppl. 3; Aids Research and Human Retroviruses; Mary Ann Liebert, Inc.

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT****Complete if Known**

Application Number	10/576,981
Filing Date	March 2, 2007
First Named Inventor	Martin Leonard Ashdown
Art Unit	1648
Examiner Name	Zachariah Lucas
Attorney Docket Number	5517-18

Sheet 10 of 11

127	Suri-Payer, et al., "CD4+CD25+ T Cells Inhibit Both the Induction and Effector Function of Autoreactive T Cells and Represent a Unique Lineage of Immunoregulatory Cells," The Journal of Immunology, vol. 160, pp. 1212-1218, D February 1998
128	TAKAHASHI, TAKESHI; Immunologic Self- Tolerance Maintained by CD20 CD4 ⁺ Naturally Anergic and Suppressive T Cells: Induction of Autoimmune Disease by Breaking Their Anergic/Suppressive State; September 10, 1998; DO. 1969-1980; V. 10, No. 12; International Immunology; Japanese Society for Immunology
129	TAN et al., "Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase" Journal of Natural Products, vol. 54, no.1, 1991, pages 143-154
130	TAWA. A. et al., "Rhabdomyosarcoma of the Urinary Bladder. Complete remission induced by Vinblastine. cis- platinum. and Bleomycin" XP.02351700 Gan to Kagaku Ryoho Japan. December 1982
131	TONIATTI, C., et al., Regulation of the Human C-Reactive Protein Gene A Major Marker of Inflammation and Cancer." XP-002351697. 1990. Molecular Biology and Medicine. Vol. 7. No.3. 1990. pgs 199-212
132	VAHLENKAMP et al., "Feline Immunodeficiency Virus infection phenotypically and functionally activates immunosuppressive CD4+CD25+ T Regulatory Cells", Journal of Immunology, 2003, pp. 4752-4761
133	VAHLENKAMP et al., "The role of CD4+ CD25+ regulatory T cells in viral infections", Veterinary Immunology and Immunopathology, vol. 108, pp. 219-225, 2005
134	Verma, et al., "Role of MHC class I expression and CD8+ T cells in the evolution of Iodine-induced thyroiditis in NOD- H2h4 and NOD mice," European Journal of Immunology, vol. 30, pp. 1191-1202, 2000
135	WANG et al., "Detection of Mammary Tumor Virus ENV Gene-like Sequences in Human Breast Cancer", Cancer Research 55, 5173-5179, November 15, 1995
136	Wong et al., "Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library," Nature Medicine, vol. 5, no. 9, pp. 1026-1031, September 17, 2002
137	Wu, et al., "Tumor necrosis factor- α regulation of CD4+ CD25+ T cell levels in NOD mice," Proceedings of the National Academy of Sciences, vol. 99, no. 19, pp. 12287-12292, September 17, 2002
138	Yoon, et al., "Cellular and Molecular Pathogenic Mechanisms of Insulin-Dependent Diabetes Mellitus," Health Aging for Functional Longevity: Molecular and Cellular Interactions in Senescence, Annals of The New York Academy of Sciences, vol. 928, pp. 200-211, April 2001
139	ZOU et al. (1999) J. Acquir. Immune Defic. Syndr. 22:31-38
140	PATENT COOPERATION TREATY, PCT International Search Report, dated 11/14/05, 4 pages

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT****Complete if Known**

Application Number	10/576,981
Filing Date	March 2, 2007
First Named Inventor	Martin Leonard Ashdown
Art Unit	1648
Examiner Name	Zachariah Lucas
Attorney Docket Number	5517-18

Sheet

11

of

11

141	International Search Report for International (PCT) Application No. PCT/AU2004/001456, mailed December 8, 2004
142	International Preliminary Report on Patentability for International (PCT) Application No. PCT/AU2004/001456, completed September 27, 2005
143	Written Opinion for International (PCT) Patent Application No. PCT/AU2004/001456, mailed December 8, 2004
144	Supplementary European Search Report for EP 03 70 1355, complete December 5, 2005
145	SUPPLEMENTARY PARTIAL EUROPEAN SEARCH REPORT, dated 8/8/08, 8 pages
146	European Examination Report, dated July 9, 2008, 10 pages
147	European Supplementary Search Report, dated August 6, 2008, 6 pages

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.